GlaxoSmithKline plc (GSK – Free Report) and its partner Vir Biotechnology, Inc. (VIR – Free Report) announced that they have signed a binding agreement to expand their existing collaboration to advance new therapies for influenza and other respiratory viruses.
We note that Glaxo/Vir Biotech are already developing two monoclonal antibody (mAb) candidates – VIR-7832 and VIR-7831, as a potential treatment of COVID-19 under their existing coronavirus collaboration agreement.
With the expanded collaboration, the companies are looking to develop VIR-2482, an intramuscularly administered investigational mAb for treating influenza A. The companies will also develop next-generation antibodies for the prevention/treatment of influenza over a research period of three years.
Per the latest agreement,Glaxo will make an upfront payment of $225 million along with an equity investment worth $120 million in Vir Biotech. Also, Glaxo will have an exclusive option to co-develop VIR-2482 after Vir Biotech completes and reports phase II study outcomes. A phase I study on VIR-2482 has already been completed. If Glaxo exercises its option it will have to have to pay $300 million option fee to Vir Biotech. VirBiotech is also eligible to receive up to $200 million from Glaxo upon successful delivery of pre-defined regulatory milestones.
Both companies will share the development costs and profits related to the expanded agreement.
Shares of Glaxo have declined 2.4% so far this year against the industry’s increase of 1.1%.
Per the press release, Glaxo/Vir Biotech will expand their current functional genomics collaboration, which will now include other respiratory viruses along with potential pan-coronavirus therapies. Secondly, the companies will come together to develop up to three neutralizing mAbs which will be recognized using Vir Biotech’s antibody technology platform, targeting non-influenza pathogens over a research period of three years.
Glaxo also has an agreement with Sanofi (SNY – Free Report) to develop a COVID-19 vaccine. The companies are developing their adjuvanted recombinant protein-based COVID-19 vaccine candidate, which is currently being evaluated in a phase I/II study.
Zacks Rank & Key Pick
Glaxo currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the large-cap pharma sector is Johnson & Johnson (JNJ – Free Report) , which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Johnson & Johnson’s earnings estimates have been revised 6.6% and 4.8% upward for 2021 and 2022, respectively, over the past 60 days. The stock has gained 5.2% year to date.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research SherazMian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.